L3 Pharmacogenomics
The stroke pharmacogenomics line is focused on the search of genes influencing the response to drugs commonly used in stroke. The most commonly drugs administrated to stroke patients are recombinant tissue plasminogen activator (rTPA) in the acute phase and antiplatelet and oral anticoagulants to prevent secondary events.
Our projects use the GWAS strategy, integrated with other -omic technologies, such as transcriptomics or proteomics, to identify new genes influencing the efficacy/safety profile of these drugs. The results from these studies could lead to a more personalized medicine where each patient is treated with the best drug option based on their demographic, clinical and genetic profile. In an active project in this field, we are investigating the genes associated with a relatively common side effect of rTPA, the haemorrhagic transformation. In the latest publication in this area, we found the gene RP11-362K2.2:RP11-767I20.1 to be associated with the occurrence of parenchymal haematoma, a complication of the reperfusion therapy with rtPA (Muiño E. et al; J Clin Med. 2021).
Other projects are also focused on the investigation of genes associated with stroke recurrence and bleeding complications in patients treated with oral anticoagulants (Cullell N. et al; Sci Rep. 2020).
